Diabetes Mellitus, Type 2, Hypertension
Conditions
Brief summary
The study was designed to evaluate the safety and pharmacokinetic interaction between THP-00101 and THP-00102 in healthy adult volunteers.
Detailed description
The study consists of 2 periods of THP-00101 or THP00102 administration over 5 days and combined administration of THP-00101 and THP00102 over 5 days in two arms. Dapagliflozin (18 Subjects): Tx A (5 days) -\> Tx B (5 days) Treatment A: THP-00101 (Dapagliflozin) 1 tablet/5 days Treatment B: THP-00101 (Dapagliflozin) 1 tablet/5 days + THP-00102 (Telmisartan) 1 tablet/5 days Telmisartan (32 Subjects): Tx C (5 days) -\> Tx C (5 days) Treatment C: THP-00102 (Telmisartan) 1 tablet/5 days Treatment B: THP-00102 (Telmisartan) 1 tablet/5 days + THP-00101 (Dapagliflozin) 1 tablet/5 days
Interventions
DRUGTHP-00101 (Dapagliflozin) 10mg
Dapagliflozin 10mg Tablet / 5 days in period 1 and period 2 will be given to Arm A Dapagliflozin 10mg Tablet / 5 days in period 2 will be given to Arm B
DRUGTHP-00102 (Telmisartan) 80mg
Telmisartan 80mg Tablet / 5 days in period 1 and period 2 will be given to Arm B Telmisartan 80mg Tablet / 5 days in period 2 will be given to Arm A
Sponsors
THPharm Corp.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
A two-arm, open-label, single-sequence, multiple oral dosings, crossover clinical trials THP-00101 (Dapagliflozin) 10mg (18 Subjects): Tx A (5 days) -\> Tx B (5 days) Treatment A: THP-00101 (Dapagliflozin) 10mg/5 days Treatment B: THP-00101 (Dapagliflozin) 10mg/5 days + THP-00102 (Telmisartan) 80mg/5 days THP-00102 (Telmisartan) 80mg (32 Subjects): Tx C (5 days) -\> Tx B (5 days) Treatment C: THP-00102 (Telmisartan) 80mg/5 days Treatment B: THP-00102 (Telmisartan) 80mg/5 days + THP-00101 (Dapagliflozin) 10mg/5 days
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. A person who is 19 years of age or older at the screening visit 2. A person who weighs at least 55 kg (50 kg for women) and has a body mass index (BMI) of at least 18.0 kg/m2 and at least 30.0 kg/m2 at screening visit ☞ BMI (kg/m2) = Weight (kg)/ {Height (m)}2 3. A person who has no clinically meaningful congenital or chronic disease and has no pathological symptoms or findings as a result of medical examination at a screening visit 4. A person who has been determined to be suitable for the test as a result of diagnostic tests such as hematology tests, hematochemical tests, serum tests, urine tests, etc., set and conducted by the test manager (or delegated test doctor) according to the characteristics of clinical drugs 5. A person who agrees to exclude the possibility of pregnancy using a medically recognized contraceptive method\* (except hormones) and does not provide sperm or eggs from the date of first administration of the clinical trial drug to 14 days after the date of last clinical trial drug administration \*medically-accepted Contraceptive methods: a combination of intrauterine devices, vasectomy, tubular ligation, and blocking contraception (male condoms, female condoms, cervical caps, contraceptive septum, sponge, etc.) or a combination of two or more blocking contraceptives 6. A person who has received and understood sufficient explanation of the purpose, contents, characteristics of clinical trial drugs, expected abnormal cases, etc., and signed the consent form according to his/her free will
Exclusion criteria
1. A person who has or has a history of clinically significant diseases corresponding to the digestive system, cardiovascular system, endocrine system, respiratory system, blood and tumor, infectious disease, kidney and urinary system, mental and nervous system, musculoskeletal system 2. A person who has a history of gastrointestinal surgery (excluding simple appendectomy or hernia surgery) or has gastrointestinal diseases that may affect drug absorption 3. Those who have taken drug metabolism-inducing and inhibiting drugs such as barbital drugs within one month of the first administration date, or drugs that may interfere with this clinical trial within 10 days of the first administration (however, in consideration of pharmacokinetic and pharmacokinetic characteristics of combination drugs it may consider as possible) 4. A person who participates in other clinical trials or biological equivalence tests within six months of the first administration and administered clinical trial drugs 5. A person who has donated whole blood within 8 weeks of the first administration, donated ingredients within 2 weeks or received a blood transfusion within 4 weeks from the first administration 6. A person who meets the following conditions within one month of the first dose date * Men consume an average of 21 cups/week of alcohol * Women consume an average of 14 cups/week of alcohol (1 glass = 50mL of soju, 30mL of spirits, or 250mL of beer) * An average of more than 20 cigarettes a day 7. A patient who falls under the following * Patients with a history of hypersensitivity to the main ingredient or additive of this drug * Type 1 diabetes patient with diabetic ketoacidosis * Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption * A patient on dialysis * Patients with severe liver disorders, biliary obstruction, or bile congestion (mostly this drug is excreted as bile). A decrease in liver cleaning rate can be expected in patients with bile congestion, biliary obstruction disease, or liver failure.) * Patients with hereditary angioedema, or patients with a history of angioedema when treated with ACE inhibitors or angiotensin II receptor antagonists * Combination with aliskiren-containing preparations in patients with diabetes or moderate to severe renal disabilities (glomerular filtration rate \<60mL/min/1.73m2) 8. For reasons other than the above selection and
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics - AUCτ,ss | Day 1 to Day 11 | AUCτ,ss of Dapagliflozin & Telmisartan |
| Pharmacokinetics - Cmax,ss | Day 1 to Day 11 | Cmax,ss of Dapagliflozin & Telmisartan |
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Day 1 to Day 17 | Evaluate incidents rate of Adverse Event of Treatment-Emergent Adverse Event and compare concomitant medication usage |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics - Vdss/F | Day 1 to Day 11 | Vdss/F of Dapagliflozin & Telmisartan |
| Pharmacokinetics - Tmax,ss | Day 1 to Day 11 | Tmax,ss of Dapagliflozin & Telmisartan |
| Pharmacokinetics - PTF | Day 1 to Day 11 | Peak-trough Fluctuation of Dapagliflozin & Telmisartan |
| Pharmacokinetics - Cmin,ss | Day 1 to Day 11 | Cmin,ss of Dapagliflozin & Telmisartan |
| Pharmacokinetics - CLss/F | Day 1 to Day 11 | CLss/F of Dapagliflozin & Telmisartan |
Countries
South Korea
Outcome results
None listed